LIVE NCPD WEBINARS: July 1 and August 12, 2021

Summer Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Prostate Cancer

Register Now

Register for these complimentary events with the “Register Now ” button above,
which will take you to our Zoom registration page.

All events moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, July 1, 2021 from 5:00 PM – 6:00 PM Eastern Time

Charles J Ryan, MD
Professor of Medicine
BJ Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota
Brenda Martone, MSN, NP-BC, AOCNP
Northwestern Medicine
Northwestern Memorial Hospital
Chicago, Illinois


Thursday, August 12, 2021 from 5:00 PM – 6:00 PM Eastern Time

A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana
Ronald Stein, JD, MSN, NP-C, AOCNP
Clinical Instructor of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, California



These activities are supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Topics to Be Discussed

  • Overview of the incidence and prognosis of prostate cancer; patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting patient care (eg, Gleason score, PSA, PSA doubling time)
  • Defining nonmetastatic (M0) castration-resistant prostate cancer (CRPC) in clinical practice; efficacy of next-generation antiandrogen agents (apalutamide, darolutamide and enzalutamide), practical integration into the management of M0 disease and the spectrum and frequency of toxicities, including CNS-related adverse events (eg, fatigue, seizure, falls)
  • Clinical, biologic and practical factors (eg, age, duration of therapy, extent and sites of metastases) guiding the choice between secondary hormonal therapy and chemotherapy for metastatic hormone-sensitive prostate cancer; effectiveness and tolerability of antiandrogen agents (eg, enzalutamide or apalutamide) or chemotherapy (eg, docetaxel) in combination with androgen deprivation therapy (ADT) compared to ADT alone
  • Clinical and biologic factors affecting the selection and sequencing of secondary hormonal therapy, chemotherapy and other therapeutic modalities (eg, cabazitaxel, radium-223) for patients with metastatic CRPC
  • Rationale and clinical strategy for molecular testing for deleterious germline or somatic HRR (homologous recombination repair) gene mutations in patients with metastatic CRPC; mechanism of action, effectiveness and side effects of PARP inhibitors (ie, olaparib and rucaparib) and practical incorporation into therapy

Target Audience
These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of each activity, participants should be able to

  • Apply existing and emerging research data in the therapeutic and supportive care of patients with early and advanced prostate cancer.
  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Counsel patients with hormone-sensitive metastatic prostate cancer regarding the use of cytotoxic and secondary hormonal therapy to ensure appropriate and informed shared decision-making.
  • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic CRPC.
  • Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or other DNA damage repair pathway abnormalities, and advise individuals found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
  • Educate patients about the side effects associated with approved therapies commonly used for advanced prostate cancer, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Recall available data and the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
Each educational activity for 1 contact hour is provided by RTP.

Each activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for each event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Ryan, Ms Martone and Mr Stein have no relevant conflicts of interest to disclose. The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr SartorConsulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien Muenchen AG, Janssen Biotech Inc, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Invitae, Janssen Biotech Inc, Merck, Progenics Pharmaceuticals Inc, Sanofi Genzyme, SOTIO LLC.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.